Health Innovation
5 University Spinout Health Startups Moving Research Into Products
DealBio tracks early-stage university spinout health startups across Europe and North America. These 5 are translating academic research into diagnostics, therapies and research platforms.
- University Spinout
- Academic Founder
- Biotech
- Diagnostics
DealBio tracks early-stage university spinout health startups across Europe and North America. These 5 are translating academic research into diagnostics, therapies and research platforms.
Across these spinouts, the university origin has already been converted into one of three commercial assets: protected IP, a productized research platform or a defined development program. Academic science provides the starting advantage, but the startup becomes more tangible once the technology has a clear owner, user and route to market.
The group also shows that spinouts do not all need the same proof. Research tools can begin validating demand through industry use and paid projects, while therapeutics need progressively stronger preclinical and clinical evidence. The university connection is most useful when it has already been translated into the next proof point the business actually needs.
At a Glance
- EVIIVESwitzerland2022Liquid-biopsy diagnostics
- GlioCARTSwitzerland2025Dual-action CAR-T therapy
- UNOMRSwitzerland2025Single-molecule protein analysis
- OrganAIDSpain2025Patient-derived tissue models
- Alvara TherapeuticsDenmark2026Keap1-Nrf2 small molecules
01
EVIIVE
Developing blood tests that predict which cancer patients respond to immunotherapy.
- Country
Switzerland- Founded
- 2022
- Sector
- Diagnostics
- Funding stage
- Seed or earlier
- Founders
Why EVIIVE stands out
EVIIVE grew out of University of Zurich research on extracellular vesicles and cancer immunology. Human melanoma evidence, non-dilutive funding and clinical links to University Hospital Zurich have moved the spinout toward a defined blood-based treatment-selection product.
The startup has also partnered with Ymmunobio on a companion diagnostic, adding an external drug-development use case around the academic platform.
What EVIIVE is building
EVIIVE is developing IMPASS and IMPACT to profile extracellular vesicles in blood and identify molecular patterns associated with immunotherapy response.
The first application is advanced melanoma, with the broader platform intended to support precision diagnostics around immune response and treatment selection.
02
GlioCART
Developing CAR-T therapy targeting glioblastoma and tumor-supporting immune cells.
- Country
- Switzerland
- Founded
- 2025
- Sector
- Biotech
- Funding stage
- Seed or earlier
Why GlioCART stands out
GlioCART has secured exclusive worldwide rights to University of Basel CAR-SGRP technology and has preclinical evidence in glioblastoma models. Its lead construct eradicated mosaic tumors in mice in work published in Nature Communications.
Venture Kick funding and selection for Venture Leaders Biotech add non-dilutive and commercialization support around the licensed academic asset.
What GlioCART is building
GlioCART is developing a dual-action CAR-T therapy that targets EGFRvIII-positive glioblastoma cells and locally releases a CD47 blocker.
The design combines direct tumor-cell killing with activation of nearby myeloid immune cells, addressing tumor heterogeneity and the immunosuppressive microenvironment.
03
UNOMR
Building nanopore sensors that analyze protein modifications one molecule at a time
- Country
- Switzerland
- Founded
- 2025
- Sector
- Biotech
- Funding stage
- Seed or earlier
Why UNOMR stands out
UNOMR commercializes nanopore research developed at ETH Zurich. It has secured CHF 300,000 in competitive non-dilutive funding and is working with Nestlé on single-protein glycosylation measurement.
The combination of university-derived sensing IP and an industry application gives the spinout an early route from academic instrumentation toward recurring R&D use.
What UNOMR is building
UNOMR is building an adjustable nanopore sensor that measures individual protein molecules and chemical modifications such as glycosylation.
Its first applications focus on protein size and glycosylation, with a benchtop format aimed at pharma, biotech and medical-nutrition research.
04
OrganAID
Testing drug responses in patient-derived tissue models with AI analysis.
- Country
Spain- Founded
- 2025
- Sector
- Biotech
- Funding stage
- Seed or earlier
Why OrganAID stands out
OrganAID was established from University of Barcelona and Pompeu Fabra University technology combining patient-derived tissue models with predictive image analysis. It also won a place in Insud Pharma’s ChemoStart program.
CEO Víctor Bañares adds repeat company-building experience to a scientific team with academic expertise in organoids, genetics and computational biology.
What OrganAID is building
OrganAID grows patient-derived organoids and uses AI image analysis to measure toxicity and treatment response.
The platform is being developed as a research service for pharmaceutical and biotechnology teams that want more patient-specific biological information during drug testing.
Developing small-molecule medicines for chronic kidney disease.
- Country
Denmark- Founded
- 2026
- Sector
- Biotech
- Funding stage
- Seed or earlier
- Founders
Why Alvara Therapeutics stands out
Alvara Therapeutics translates 11 years of University of Copenhagen research on the Keap1-Nrf2 pathway into a drug-development startup. It joined BioInnovation Institute’s Venture Lab with a €560,000 convertible loan allocation and venture-development support.
Several cell-active inhibitor series were already developed before company formation, giving the spinout a defined medicinal-chemistry starting point.
What Alvara Therapeutics is building
Alvara is developing non-covalent small molecules that inhibit the Keap1-Nrf2 interaction and activate antioxidant and anti-inflammatory responses.
The first therapeutic focus is chronic kidney disease, where the team is advancing compounds from academic discovery toward preclinical drug development.
Deal Sourcing for Investors
Looking for More Startups Like These?
DealBio helps investment teams discover, research, and monitor early-stage healthcare and life sciences startups aligned with their investment criteria.
Investment perspective
The most useful distinction in this group is between academic validation and commercial validation. A university can establish that the science works; the startup still has to show that someone outside the originating lab will use, fund or develop it. Industry collaborations, licensed IP and external development programs are therefore more informative than the spinout label itself.
That creates different near-term milestones across the group. Platform businesses can prove themselves through repeat use, standardization and customer demand, while drug developers have to convert academic mechanisms into compounds with a credible preclinical path. The stronger spinouts are the ones where the next value-creating milestone is already happening inside the startup rather than remaining dependent on the university.
Methodology
DealBio selected these five early-stage university spinouts because each is commercializing a defined academic asset in health or life sciences. The selection focuses on startups where university research is connected to a specific product, licensed technology or development program.
DealBio builds its Startup Briefs using publicly available startup materials, ecosystem sources, market references and professional profiles.